Drugs / MIB-626
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05759468 Comparator | Apr 2023 → Nov 2026 expected | diabetic kidney disease, type 2 diabetes mellitus | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIB-626 | “The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of...” NCT05759468 ↗ |
| Known as | NMN | “The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of...” NCT05759468 ↗ |
| Route | Oral | “after its daily oral administration” NCT05759468 ↗ |